ESR1 and breast carcinoma: In the present study, two TAM-resistant ER-positive/ERBB2-positive breast cancer cell lines (MCF7/HER2 and BT474) and one TAM-sensitive ER-positive/ERBB2-negative breast cancer cell line (MCF7) were used to model the effects of TAM treatment on breast cancers with either low or high levels of NFκB and AP-1 transcriptional activity, and assess the TAM interacting effects of drugs (PA, PS341) potentially capable of lowering NFκB and AP-1 activities.